Navigation Links
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Date:11/8/2007

- Labeling Now Includes Lower Once-Daily Starting Dose and Data from First

Randomized Trial of SPRYCEL and Gleevec(R)*(imatinib mesylate) -

PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for SPRYCEL to include a lower recommended starting dose of 100 mg once daily and safety and efficacy data in a greater number of patients with chronic-phase chronic myeloid leukemia (CML) resistant or intolerant to prior therapy including Gleevec. The product labeling now also includes data from the first randomized trial of SPRYCEL and Gleevec. SPRYCEL is indicated for the treatment of adults with chronic-, accelerated-, or myeloid or lymphoid blast-phase CML with resistance or intolerance to prior therapy including Gleevec. The effectiveness of SPRYCEL is based on hematologic and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.

"The new, lower once-daily dose reduces the incidence of some side effects while preserving the efficacy of SPRYCEL for patients with chronic-phase CML no longer responding to currently-approved therapies," said Dr. Hagop Kantarjian, M.D., Chairman and Professor, Leukemia Department, MD Anderson Cancer Center. "Importantly, the new clinical data now included in the labeling provides further evidence to support the use of SPRYCEL to treat patients with chronic-phase CML, if their disease is no longer responding to currently available treatment including Gleevec."

The updated labeling was granted priority review and was approved in six months
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Bellevue city councilmember John Stokes ... solutions for people with disabilities on Friday, June ... , The exhibit hall, which is free ... Sunday, will feature leading manufacturers and suppliers of ... eyegaze technologies, computer applications, and home modification equipment. ...
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... June 19, 2013   NineSigma , Inc., of ... year following its launch, NineSights.com is now ... point for the worldwide community of innovators. ... environmental sustainability experts, NineSights stands out for its large ... scientific and technical disciplines, all vetted by NineSigma. The ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
Breaking Biology Technology:City of Bellevue, Wash., Welcomes Assistive Technology Exhibit Hall 2Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... ANNAPOLIS, Md., May 15 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today reported financial ... 31, 2009.For the first quarter of 2009, PharmAthene recognized ... the same period of 2008. Revenues for the ...
... /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin Board: ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... present at the upcoming China Rising Conference hosted ... May 18, 2009 and the 3rd Annual China,Dragon ...
... ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ ... . , ... Atlanta, GA (PRWEB) ... launch of the Cryptonite™ HV Filter Module for Cryptosporidium and ...
Cached Biology Technology:PharmAthene Reports First Quarter 2009 Financial and Operational Results 2PharmAthene Reports First Quarter 2009 Financial and Operational Results 3PharmAthene Reports First Quarter 2009 Financial and Operational Results 4PharmAthene Reports First Quarter 2009 Financial and Operational Results 5PharmAthene Reports First Quarter 2009 Financial and Operational Results 6PharmAthene Reports First Quarter 2009 Financial and Operational Results 7China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4ElutraSep Inc. Announces the Launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia Testing 2
(Date:6/19/2013)... the most potent physiological anabolic agent for tissue-building ... of lipids, protein and carbohydrates, and inhibiting their ... also plays a major role in stimulating glucose ... metabolized and removed from the blood following meals. ... mechanisms by which insulin regulates glucose uptake in ...
(Date:6/19/2013)... expected to contribute to a very large and potentially ... a University of Michigan ecologist and colleagues who released ... Chesapeake Bay. , The Gulf forecast, one of two ... for an oxygen-depleted, or hypoxic, region of between 7,286 ... the 10 largest on record. , The low end ...
(Date:6/18/2013)... United Kingdom, the Energy Department,s National Renewable Energy ... recently published a paper describing a novel cellulose-degrading ... quadripunctata , commonly known as the gribble. ... a relatively unique ability to produce their own ... down the biomass they eat. New biomass-degrading enzymes ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... an important signaling molecule in plants - as in ... herb as a model plant, researchers have found that ... in plants. In collaborative work with the research ... doctoral student at the Botany Department, University of Delhi, ...
... Press announces the latest addition to its Cumulative Techniques ... Cumitech 46 -- Laboratory Procedures for Diagnosis of ... provide guidance to the laboratory personnel and other members ... ordering and application of tests for the diagnosis and ...
... a neutrophil releases a protein that can suppress glucose ... found. Neutrophils, a type of white blood ... to have a connection with glucose levels. During bacterial ... frequently results in hypoglycemia. In addition, many patients with ...
Cached Biology News:Nitric oxide regulates plants as well as people 2
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Nonanoyl-N-methylglucamide ... properties. Can be readily removed by ... Purity: ≥98% by HPLC. ... nm): 2 O. CMC 19 ...
...
Biology Products: